China-based smart healthcare service platform Jianke.com (Fangzhou Inc.) has filed for an initial public offering (IPO) on the Hong Kong Stock Exchange. Citibank, UBS, and ABC International will act as co-sponsors. The filing marks a significant step in the company’s expansion plans, aiming to leverage its comprehensive healthcare services and robust user base.
Company Profile and Services
Founded in 2015, Jianke.com focuses on chronic disease management and offers a suite of core businesses, including comprehensive medical services, online retail pharmacy services, customized content, and marketing solutions. Comprehensive medical services encompass Hospital to Home (H2H) services and offline medical services. Online retail pharmacy services involve a variety of medical and healthcare products, particularly prescription drugs, delivered through third-party express companies. Customized content and marketing solutions are primarily targeted at pharmaceutical enterprises, with digital marketing conducted through academic communities, specialized chronic disease management platforms, and health science popularization platforms.
User Base and Financial Performance
As of June 30, 2022, Jianke.com’s platform is subscribed to by 30.9 million users and 200,000 physicians from over 14,800 medical institutions. The company generated RMB 1.759 billion (USD 245.9 million) in revenues in 2021 and RMB 993 million (USD 138.8 million) during the first half of this year, representing a 30.7% year-on-year increase. This growth underscores Jianke.com’s position as a leading player in the smart healthcare sector, with a strong focus on chronic disease management.-Fineline Info & Tech
